Critically ill patients are at-risk for gastrointestinal bleeding and ulceration, which has led to widespread use of stress ulcer prophylaxis to preempt those conditions. However, the therapy can have negative effects and put patients at increased risk of pneumonia and Clostridium difficile infection.
“Suppressing gastric acid is necessary in select critically ill patients to reduce GI bleeding, but doing so also affects its effectiveness as an antiseptic barrier,” said Andrew Faust, PharmD, one of the study’s co-authors. “Preventing GI bleeding through acid-suppressive therapy, especially proton pump inhibitors, may increase a patient’s risk for serious and potentially life-threatening infectious complications.”
Dr. Faust and other authors urged using the therapy only when patients meet specific criteria and encouraged implementing a risk-scoring tool to cut down on overuse of SUP.
More articles on patient safety:
What happens when a hospital NICU goes handshake-free?
Hot or cool: Water temperature does not impact bacteria removal during hand-washing, study shows
4 findings on infection prevention in nonacute care settings
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
